Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing

Cancer Immunology, Immunotherapy

Volumn 58, Issue 11, 2009, Pages 1889-1898

  Kute, Timothy E ^a   Savage, Lori ^a   Stehle Jr , John R ^a   Kim Shapiro, Jung W ^a   Blanks, Michael J ^a   Wood, James ^a   Vaughn, James P ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ADCC; Breast cancer; BT 474; Herceptin; Resistance; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CELL CYCLE; CELL FRACTIONATION; CELL GROWTH; CELL ISOLATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG SENSITIVITY; GRANULOCYTE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; ANIMAL; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; RECEPTOR, ERBB-2;

EID: 69049115067     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0700-0     Document Type: Article

References (32)

1. M Barok J Isola Z Palyi-Krekk P Nagy I Juhasz G Vereb P Kauraniemi A Kapanen M Tanner G Vereb J Szollosi 2007 Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance Mol Cancer Ther 6 2065 2072
2. H Burris III D Yardley S Jones G Houston C Broome D Thompson FA Greco M White J Hainsworth 2004 Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer J Clin Oncol 22 1621 1629
3. HJ Burstein LN Harris R Gelman SC Lester RA Nunes CM Kaelin LM Parker LW Ellisen I Kuter MA Gadd RL Christian PR Kennedy VF Borges CA Bunnell J Younger BL Smith EP Winer 2003 Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol 21 46 53
4. P Carter L Presta CM Gorman JB Ridgway D Henner WL Wong AM Rowland C Kotts ME Carver HM Shepard 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285 4289
5. G Cartron L Zhao-Yang M Baudard T Kanouni V Rouille P Quittet B Klein JF Rossi 2008 Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study J Clin Oncol 26 2725 2731
6. A Citri Y Yarden 2006 EGF-ERBB signalling: towards the systems level Nat Rev Mol Cell Biol 7 505 516
7. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 443 446
8. Drugger DL, Hollingshead PG, Wong D, Romero M, Erickson SL, RH S (2002) Acquistion of Herceptin resistance by HER2 mutation in the HER2 transgenic mouse breast cancer model. Proceedings of the 93rd Annual Meeting of the American Association Cancer Research, San Francisco
9. R Gennari S Menard F Fagnoni L Ponchio M Scelsi E Tagliabue F Castiglioni L Villani C Magalotti N Gibelli B Oliviero B Ballardini G Da Prada A Zambelli A Costa 2004 Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 Clin Cancer Res 10 5650 5655
10. J Glamann AJ Hansen 2006 Dynamic detection of natural killer cell-mediated cytotoxicity and cell adhesion by electrical impedance measurements Assay Drug Dev Technol 4 555 563
11. LN Klapper H Waterman M Sela Y Yarden 2000 Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2 Cancer Res 60 3384 3388
12. KS Klos X Zhou S Lee L Zhang W Yang Y Nagata D Yu 2003 Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone Cancer 98 1377 1385
13. WJ Kostler B Schwab CF Singer R Neumann E Rucklinger T Brodowicz S Tomek M Niedermayr M Hejna GG Steger M Krainer C Wiltschke CC Zielinski 2004 Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer Clin Cancer Res 10 1618 1624
14. T Kute CM Lack M Willingham B Bishwokama H Williams K Barrett T Mitchell JP Vaughn 2004 Development of Herceptin resistance in breast cancer cells Cytometry A 57 86 93
15. S Mayfield JP Vaughn TE Kute 2001 DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines Breast Cancer Res Treat 70 123 129
16. Y Nagata KH Lan X Zhou M Tan FJ Esteva AA Sahin KS Klos P Li BP Monia NT Nguyen GN Hortobagyi MC Hung D Yu 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127
17. P Nagy E Friedlander M Tanner AI Kapanen KL Carraway J Isola TM Jovin 2005 Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res 65 473 482
18. R Nahta FJ Esteva 2007 Trastuzumab: triumphs and tribulations Oncogene 26 3637 3643
19. WM Nauseef 2007 Isolation of human neutrophils from venous blood Methods Mol Biol 412 15 20
20. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672
21. SA Price-Schiavi S Jepson P Li M Arango PS Rudland L Yee KL Carraway 2002 Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance Int J Cancer 99 783 791
22. T Repka EG Chiorean J Gay KE Herwig VK Kohl D Yee JS Miller 2003 Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study Clin Cancer Res 9 2440 2446
23. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
24. K Solly X Wang X Xu B Strulovici W Zheng 2004 Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays Assay Drug Dev Technol 2 363 372
25. CI Spiridon MA Ghetie J Uhr R Marches JL Li GL Shen ES Vitetta 2002 Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo Clin Cancer Res 8 1720 1730
26. CI Spiridon S Guinn ES Vitetta 2004 A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies Clin Cancer Res 10 3542 3551
27. M Tanner AI Kapanen T Junttila O Raheem S Grenman J Elo K Elenius J Isola 2004 Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer Mol Cancer Ther 3 1585 1592
28. S Varchetta N Gibelli B Oliviero E Nardini R Gennari G Gatti LS Silva L Villani E Tagliabue S Menard A Costa FF Fagnoni 2007 Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2 Cancer Res 67 11991 11999
29. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726
30. JZ Xing L Zhu JA Jackson S Gabos XJ Sun XB Wang X Xu 2005 Dynamic monitoring of cytotoxicity on microelectronic sensors Chem Res Toxicol 18 154 161
31. FM Yakes W Chinratanalab CA Ritter W King S Seelig CL Arteaga 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res 62 4132 4141
32. J Zhu X Wang X Xu YA Abassi 2006 Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays J Immunol Methods 309 25 33